Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
Journal of Cancer Research and Clinical Oncology
|
January 1, 1997
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma
G G Steger, M F Gnant, M P Djavanmard, et al.
European Cytokine Network
|
October 7, 2000
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2
G J Locker, J Kofler, B Stoiser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 19, 2005
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience
G G Steger, R Bartsch, C Wenzel, et al.
Cancer Research
|
July 1, 1997
5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients
M Müller, R M Mader, B Steiner, et al.
Cancer Immunology, Immunotherapy : CII
|
September 22, 2000
Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group
M Schmidinger, G G Steger, C Wenzel, et al.
Wiener Klinische Wochenschrift
|
September 29, 2000
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer
M Schmidinger, A C Budinsky, C Wenzel, et al.
Anti-Cancer Drugs
|
November 18, 2000
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
T Brodowicz, R M Wolfram, W J Köstler, et al.
British Journal of Cancer
|
September 11, 2003
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
G Hudelist, W J Köstler, J Attems, et al.
ESMO Open
|
May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial
P Filis, X Liu, A Matikas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?
G J Locker, G G Steger, M F Gnant, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
Journal of Cancer Research and Clinical Oncology
|
January 1, 1997
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma
G G Steger, M F Gnant, M P Djavanmard, et al.
European Cytokine Network
|
October 7, 2000
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2
G J Locker, J Kofler, B Stoiser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 19, 2005
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience
G G Steger, R Bartsch, C Wenzel, et al.
Cancer Research
|
July 1, 1997
5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients
M Müller, R M Mader, B Steiner, et al.
Cancer Immunology, Immunotherapy : CII
|
September 22, 2000
Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group
M Schmidinger, G G Steger, C Wenzel, et al.
Wiener Klinische Wochenschrift
|
September 29, 2000
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer
M Schmidinger, A C Budinsky, C Wenzel, et al.
Anti-Cancer Drugs
|
November 18, 2000
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
T Brodowicz, R M Wolfram, W J Köstler, et al.
British Journal of Cancer
|
September 11, 2003
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
G Hudelist, W J Köstler, J Attems, et al.
ESMO Open
|
May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial
P Filis, X Liu, A Matikas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?
G J Locker, G G Steger, M F Gnant, et al.
Page
of 7